Review Article
Targeted Therapies in Adult B-Cell Malignancies
Table 3
Clinical trials for multiple myeloma, based on
https://clinicaltrials.gov/, as of March 13, 2015. ASCT: autologous stem cell transplantation; PD-L-1: programmed death-1 ligand 1; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; IGF-1R: insulin growth factor-1 receptor; KIR: killer cell Ig-like receptor; DKK: Dickkopf-related protein; BTK: Bruton’s tyrosine kinase; PI3k: phosphoinositide 3-kinase; PARP: poly(ADP-ribose) polymerase.
| Multiple myeloma 1908 studies | Monoclonal antibodies 82 studies | Anti-CD38 | 4 studies | Phase 2 | Anti-IL6 siltuximab | 5 studies | Combination | Anti-CD40 | 4 studies | Phase 1/2 | Anti-transferrin R | 1 study | Phase 1/2 | Anti-GM2 | 1 study | Phase 1/2 | Anti-CD66 90Y | 1 study | + ASCT | Anti-CD45 90Y | 1 study | + allogeneic transplantation | Anti-Adhesion Mol1 | 1 study | Phase 1 | Anti-CD38 | 1 study | Combination | Anti-PDL1 | 3 studies | Phase 2 with vaccination | | | Combination with lenalidomide | Anti-IGF1R | 1 study | Phase 1 | Bevacizumab | 3 studies | Phase 2 combination | Anti-KIR | 4 studies | Phase 1 and Phase 2 | Anti-CTLA-4 | 2 studies | + allogeneic T. | Anti-CD52 | 3 studies | + allogeneic T. | Anti-DKK1 | 1 study | Randomized Phase 2 |
Anti-CD20 | 90Y/131I 2 studies | + ASCT | Cold: 3 studies | Combination | Anti-CD56 | 1 study | Phase I | Elotuzumab | 5 studies | Randomized Phase 1/2 | Anti-GRP78 (PAT-SM6) | 1 study | Phase 1 | Anti-CXCR4 | 1 study | Phase 1b | BTK inhibitors | Ibrutinib ACP-196/ACP-319 | 2 studies (+ carfilzomib) 3 studies | Phase 2 Phase 1b | PI3 kinase inhibitors | Idelalisib, BYL719, CUDC-907, nelfinavir, SOM230 LAR, and sorafenib | Phase 1/2 | Anti-CDK | Dinaciclib | Combination | Phase 1/2 | Antiproteasome | Carfilzomib Ixazomib Oprozomib Marizomib | 10 studies
| Phase 3 Phase 1 | HDAC | Ricolinostat, vorinostat | Combination
| Phase 1b
| PARP inhibitor | ABT-888 | Combination | Phase 1 |
|
|